Seer's Nanoparticle Technology Signals Paradigm Shift in Disease Research

REDWOOD CITY, CA – February 19, 2026 – This week, the scientific community is turning its attention to St. Louis, where Seer, Inc. (Nasdaq: SEER) is set to feature prominently at the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference. More than a dozen presentations by leading researchers will showcase how the company's Proteograph® Product Suite is enabling significant advances in understanding complex illnesses like cardiovascular disease, neurodegeneration, and cancer. The strong showing signifies a pivotal moment for Seer and the broader field of proteomics, highlighting the growing adoption of its nanoparticle-based technology that promises to unlock biological insights at a scale and depth previously thought unattainable.

Proteomics, the large-scale study of proteins, is fundamental to understanding health and disease. Proteins are the functional workhorses of cells, and their analysis provides a direct window into biological processes. However, the field has long been hampered by immense technical challenges. The human proteome is vast and dynamic, with protein concentrations spanning more than 10 orders of magnitude. In blood plasma, for example, a handful of high-abundance proteins like albumin can mask the presence of thousands of lower-abundance proteins that may serve as critical biomarkers for disease. Seer's technology is engineered to overcome this exact problem.

A New Frontier in Protein Analysis

At the heart of Seer's innovation is its Proteograph Product Suite, which integrates proprietary engineered nanoparticles, automation, and advanced software. Instead of relying on traditional methods that often require depleting high-abundance proteins—a process that can inadvertently remove other important proteins—Seer’s nanoparticles use physicochemical interactions to capture a broad and unbiased sample of the proteome. This approach provides a much deeper and more comprehensive view of the proteins present in a biological sample.

The power of this method will be a central theme at US HUPO. In a highly anticipated breakfast symposium, Dr. Sasha A. Singh, an Assistant Professor of Medicine at Harvard Medical School, will present groundbreaking work on atherosclerosis. Using just 75 microliters of plasma from a mouse model, her lab was able to quantify over 5,000 proteins per sample. This represents a more than tenfold increase in proteome depth compared to conventional approaches, demonstrating the platform's ability to reveal a wealth of information from minimal sample volumes. This capability is crucial for studying precious samples and for enabling large-scale, population-level studies.

"The work being presented at US HUPO reflects a broader shift in proteomics toward deeper, more scalable, and more reproducible mass spectrometry measurement of the human proteome that is enabled by the Proteograph Product Suite," said David Horn, President and Chief Financial Officer at Seer. This shift is critical, as it moves proteomics from a low-throughput, specialized research tool to a powerful engine for discovery in translational and clinical settings.

Bridging the Gap from Lab Bench to Patient Bedside

While Seer's products are currently designated for research use only, the applications being showcased at US HUPO underscore a clear trajectory toward clinical relevance. The ultimate goal of this research is to translate laboratory discoveries into tangible benefits for human health, such as new diagnostic tests and targeted therapies. The conference agenda is filled with examples of this translational potential.

Dr. Nathan Basisty, an NIH Distinguished Scholar from the National Institute on Aging, will deliver a plenary talk on how advanced proteomics is accelerating geroscience—the study of aging biology. His work explores the development of biomarkers and therapeutic strategies to promote healthy aging, a field with immense public health implications. Other presentations will delve into the molecular drivers of neurodegeneration, the search for new protein-based tests for early lung cancer detection, and the systemic changes that occur in breast cancer patients undergoing chemotherapy. This breadth of research demonstrates the platform's versatility and its potential to impact nearly every area of medicine.

By enabling deep, unbiased, and reproducible protein analysis at scale, the Proteograph platform is helping researchers identify and validate novel biomarkers. These biological signatures can signal the presence of disease long before symptoms appear, monitor disease progression, and predict a patient's response to treatment. While the path from a research biomarker to an FDA-approved clinical test is long and rigorous, the foundational work being presented at US HUPO is an essential first step in that journey, addressing long-standing hurdles related to reproducibility and scale.

Navigating a Competitive and Growing Market

Seer's scientific momentum comes at a time of explosive growth in the proteomics market, which is projected to more than double in size to over $70 billion by 2030. This growth is fueled by increasing investment in precision medicine, drug discovery, and a deeper understanding of disease biology. Seer is positioning itself as a key enabler of this growth, but it operates in a competitive landscape that includes established mass spectrometry giants like Bruker and Agilent, as well as companies with different technological approaches, such as SomaLogic's affinity-based platform.

As an early-stage life sciences company, Seer's financial profile reflects its focus on innovation and market development over short-term profitability. The company maintains a strong cash position to fund its ambitious research and commercialization goals, backed by significant institutional investment. However, it continues to post substantial losses as it invests heavily in R&D and building its market presence. Investors will be closely watching the company's upcoming financial results and its ability to convert growing scientific validation into a sustainable revenue stream.

The widespread adoption and high-impact research presented at a prestigious venue like US HUPO serve as powerful validation of the company’s strategy. As David Horn noted, "As researchers apply the Proteograph solution to their complex disease models and large-scale cohorts, we are seeing strong validation of the Proteograph’s scientific impact and its strategic importance to advancing translational research at scale.” This external validation is critical for building commercial traction and solidifying Seer's position as a leader in the next generation of proteomics.